Allogene Therapeutics (NASDAQ:ALLO) Stock Price Expected to Rise, Citizens Jmp Analyst Says

Key Points

• Analysts raised price targets: Citizens Jmp bumped its target on ALLO from $5 to $8 with a "market outperform" call (implying ~163% upside), and several other firms lifted targets (HC Wainwright to $12, Canaccord to $14), leaving a consensus "Moderate Buy" target near $8.91.
• Positive clinical news drove interest: Interim ALPHA3 data showed 58.3% MRD clearance vs. 16.7% in observation, a 97.7% median ctDNA drop and no reported CRS/ICANS/GvHD so far, prompting heavy media coverage and elevated options activity.
• Dilution and insider selling are risks: Allogene filed to sell $175 million of common stock (plus a $26.25M option), which could dilute holders, and insiders have recently sold shares (278,452 shares sold in the last 90 days), potentially offsetting positive momentum.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) had its target price raised by stock analysts at Citizens Jmp from $5.00 to $8.00 in a report issued on Tuesday,Benzinga reports. The firm presently has a "market outperform" rating on the stock. Citizens Jmp's price target would indicate a potential upside of 163.24% from the stock's current price.

ALLO has been the subject of a number of other research reports. HC Wainwright boosted their target price on Allogene Therapeutics from $8.00 to $12.00 and gave the stock a "buy" rating in a report on Tuesday. Robert W. Baird upped their price target on Allogene Therapeutics from $7.00 to $9.00 and gave the company an "outperform" rating in a research report on Tuesday. Canaccord Genuity Group reissued a "buy" rating and issued a $14.00 price target on shares of Allogene Therapeutics in a research note on Friday, March 13th. UBS Group initiated coverage on Allogene Therapeutics in a research note on Wednesday, January 7th. They set a "buy" rating and a $8.00 target price for the company. Finally, Citigroup reaffirmed an "outperform" rating on shares of Allogene Therapeutics in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $8.91.

Allogene Therapeutics Stock Performance

Allogene Therapeutics stock opened at $3.04 on Tuesday. Allogene Therapeutics has a one year low of $0.86 and a one year high of $4.46. The business has a fifty day moving average of $2.29 and a two-hundred day moving average of $1.71. The company has a market cap of $740.84 million, a P/E ratio of -3.49 and a beta of 0.53.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.08. Sell-side analysts predict that Allogene Therapeutics will post -1.28 EPS for the current year.

Insider Buying and Selling

In related news, EVP Zachary Roberts sold 35,700 shares of the business's stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $1.77, for a total value of $63,189.00. Following the sale, the executive vice president owned 581,166 shares of the company's stock, valued at $1,028,663.82. The trade was a 5.79% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Geoffrey M. Parker sold 24,001 shares of Allogene Therapeutics stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $1.76, for a total value of $42,241.76. Following the completion of the transaction, the chief financial officer owned 1,252,795 shares of the company's stock, valued at approximately $2,204,919.20. The trade was a 1.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 278,452 shares of company stock valued at $534,053 over the last 90 days. 13.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Allogene Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in ALLO. Savant Capital LLC bought a new stake in Allogene Therapeutics in the third quarter valued at about $27,000. Russell Investments Group Ltd. boosted its position in shares of Allogene Therapeutics by 11,159.8% during the third quarter. Russell Investments Group Ltd. now owns 21,844 shares of the company's stock worth $27,000 after buying an additional 21,650 shares during the period. Mercer Global Advisors Inc. ADV acquired a new position in shares of Allogene Therapeutics during the third quarter worth about $30,000. Caitong International Asset Management Co. Ltd boosted its position in shares of Allogene Therapeutics by 5,267.6% during the third quarter. Caitong International Asset Management Co. Ltd now owns 24,047 shares of the company's stock worth $30,000 after buying an additional 23,599 shares during the period. Finally, Brighton Jones LLC boosted its position in Allogene Therapeutics by 81.6% during the third quarter. Brighton Jones LLC now owns 25,168 shares of the company's stock valued at $31,000 after purchasing an additional 11,311 shares during the last quarter. Institutional investors own 83.63% of the company's stock.

Key Allogene Therapeutics News

Here are the key news stories impacting Allogene Therapeutics this week:

• Positive Sentiment: Interim pivotal trial result — ALPHA3 showed 58.3% MRD clearance for Cema‑Cel vs. 16.7% in observation (41.6 ppt absolute difference), a 97.7% median drop in plasma ctDNA by day 45, and no cases of CRS, ICANS, GvHD or treatment‑related serious AEs reported so far; company flagged mid‑2027 interim EFS and mid‑2028 primary EFS. Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial
• Positive Sentiment: Multiple outlets highlight the clinical finding that residual lymphoma cells were cleared in early data cuts, increasing confidence in Allogene’s off‑the‑shelf CAR‑T approach and widening investor interest. Allogene’s off-the-shelf CAR-T erases lingering lymphoma cells in early slice of data
• Positive Sentiment: Market reaction and exposure — press summaries and coverage (BioSpace, STAT, MarketWatch) and heavy options activity (≈6,076 call contracts, ~901% above typical) point to speculative and institutional buying interest. Allogene stock sails after CAR T clears residual lymphoma in early data cut
• Positive Sentiment: Analyst bullishness — Jefferies issued a Buy and coverage notes highlight large upside (consensus price targets well above current levels), supporting momentum. Allogene Therapeutics NASDAQ: ALLO Earns Buy Rating from Analysts at Jefferies Financial Group
• Neutral Sentiment: Trading actions — shares were temporarily halted for “news pending” ahead of the release; the company held a conference call/webcast to discuss the results. Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial
• Negative Sentiment: Proposed equity raise — Allogene filed to sell $175M of common stock (with a 30‑day option for an extra $26.25M). That primary offering could dilute existing holders and may pressure the stock despite strong data. Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock

Allogene Therapeutics Company Profile

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company's pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.